Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.

Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators.

Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994.

PMID:
20551461
2.
3.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.

Gut. 2006 Aug;55(8):1138-44. Epub 2006 Feb 21.

4.

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.

Gut. 2006 Aug;55(8):1131-7. Epub 2006 Feb 28.

5.

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.

Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE.

Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038.

PMID:
19637334
6.

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.

Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ.

Gut. 2009 Oct;58(10):1354-62. doi: 10.1136/gut.2008.165738. Epub 2009 Jun 7.

PMID:
19505878
7.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
8.

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.

Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group.

Inflamm Bowel Dis. 2009 Jun;15(6):829-36. doi: 10.1002/ibd.20833.

PMID:
19130617
9.

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.

Hanauer SB, Strömberg U.

Clin Gastroenterol Hepatol. 2004 May;2(5):379-88.

PMID:
15118975
10.

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB.

Inflamm Bowel Dis. 2007 Jan;13(1):2-11.

PMID:
17206633
11.
12.

Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.

Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P.

Inflamm Bowel Dis. 2009 Mar;15(3):375-82. doi: 10.1002/ibd.20777.

PMID:
19009634
13.
14.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
15.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

16.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.

17.

A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.

Forbes GM, Sturm MJ, Leong RW, Sparrow MP, Segarajasingam D, Cummins AG, Phillips M, Herrmann RP.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):64-71. doi: 10.1016/j.cgh.2013.06.021. Epub 2013 Jul 19.

PMID:
23872668
18.

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.

Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S.

Inflamm Bowel Dis. 2010 Jul;16(7):1209-18. doi: 10.1002/ibd.21159.

PMID:
19918967
19.

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.

Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R.

Inflamm Bowel Dis. 2006 Jul;12(7):558-65.

PMID:
16804392
20.

Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study.

Omer B, Krebs S, Omer H, Noor TO.

Phytomedicine. 2007 Feb;14(2-3):87-95. Epub 2007 Jan 19.

PMID:
17240130

Supplemental Content

Support Center